atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
December 13 2021 - 6:59AM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced it has been selected for
addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective
as of market open on Monday, December 20, 2021. The NBI is a stock
market index made up of securities of Nasdaq-listed companies
classified according to the Industry Classification Benchmark as
either Biotechnology or Pharmaceuticals which also meet other
eligibility criteria.
The NBI is widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment
strategies. Exchange traded funds (ETFs) that track the NBI include
the ProShares Ultra NASDAQ Biotechnology ETF (BIB), ProShares
UltraShort NASDAQ Biotechnology ETF (BIS), Invesco NASDAQ Biotech
UCITS ETF (SBIO), and iShares Nasdaq Biotechnology Index Fund
(IBB), among others.
The NBI constituent basket has grown from 100 at the beginning
of 2010 to 274 companies today. In terms of market capitalization
for the overall group of companies in the NBI, the average was
$5.7Bn, while the weighted average was $43.9 billion.
Companies listed in the NBI must be classified as Biotechnology
& Pharmaceuticals by ICB (FTSE Russell’s Industry
Classification Benchmark); have a minimum market capitalization of
$200MM; demonstrate an average daily trading volume of at least
100,000 shares; and must be Nasdaq-listed. The index is modified
market capitalization-weighted such that constituents are capped at
8% (for the top 5) and at 4% (for the remaining) at each quarterly
index rebalance; the entire index is reviewed and reconstituted
annually in December.
“We are proud to be included in the prestigious Nasdaq
Biotechnology Index,” said Florian Brand, CEO and Co-Founder of
atai Life Sciences. “Since our IPO in June, we have continued
to make good progress against our clinical milestones. Being part
of this index enables us to reach new audiences and further
amplifies our vision: to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life."
For more information about the NASDAQ Biotechnology Index
visit www.nasdaq.com.
About atai Life Sciencesatai is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. atai was founded in 2018 as a
response to the significant unmet need and lack of innovation in
the mental health treatment landscape. atai is dedicated to
acquiring, incubating and efficiently developing innovative
therapeutics to treat depression, anxiety, addiction, and other
mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. atai has
offices in New York, London, and Berlin. For more information,
please visit www.atai.life.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. The
words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “initiate,” “could,” “would,”
“project,” “plan,” “potentially,” “preliminary,” “likely,” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these words. Forward-looking statements include express or implied
statements relating to, among other things: continued investor
confidence in atai’s platform and its potential to serve the
growing mental health crisis; the success, cost and timing of
development of our product candidates; and our business strategy
and plans. The forward-looking statements in this press release are
neither promises nor guarantees, and you should not place undue
reliance on these forward-looking statements because they involve
known and unknown risks, uncertainties, and other factors, many of
which are beyond our control and which could cause actual results,
levels of activity, performance or achievements to differ
materially from those expressed or implied by these forward-looking
statements.
We have based these forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. These
forward-looking statements are subject to a number of risks,
uncertainties, and assumptions, including without limitation the
important factors described in the section titled “Risk Factors” in
our final prospectus, dated June 17, 2021, filed with the
Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b)
under the Securities Act, and in our other filings with the SEC,
that may cause our actual results, performance or achievements to
differ materially and adversely from those expressed or implied by
the forward-looking statements. Any forward-looking statements made
herein speak only as of the date of this press release, and you
should not rely on forward-looking statements as predictions of
future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot
guarantee that the future results, performance, or achievements
reflected in the forward-looking statements will be achieved or
will occur. Except as required by applicable law, we undertake no
obligation to update any of these forward-looking statements for
any reason after the date of this press release or to conform these
statements to actual results or revised expectations.
Contact Information
Media Contact:Camilla DormerVP,
CommunicationsEmail: camilla@atai.life
Investor Contact:Chad MesserVP, Investor
RelationsEmail: chad@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024